LanzaTech Global Q2 Earnings Call Highlights

LanzaTech Global (NASDAQ:LNZA) reported second-quarter 2026 gross that was broadly level from a twelvemonth earlier, portion sharply little operating expenses helped constrictive its adjusted EBITDA nonaccomplishment arsenic the institution continues shifting from an R&D-led exemplary toward task improvement and commercialization.

The institution reported second-quarter gross of $9 million, compared with $9.1 cardinal successful the aforesaid 4th of 2025. Operating expenses declined 67% to $11.7 cardinal from $35.1 million, portion adjusted EBITDA nonaccomplishment narrowed to $7.6 cardinal from a nonaccomplishment of $29.7 cardinal a twelvemonth earlier.

→ Lumentum Just Delivered the AI Growth Investors Wanted

Chief Executive Officer Jennifer Holmgren said the quarterly results reflected "a meaningful translation successful the business," citing much unchangeable revenue, a reduced operating disbursal basal and improved adjusted EBITDA. She said LanzaTech has reduced headcount, renegotiated contracts and redirected spending toward commercialization priorities.

Revenue Mix and Cost Reductions

For the 2nd quarter, LanzaTech recorded $3.9 cardinal successful biorefining revenue, $1.3 cardinal from associated improvement and declaration research, and $3.8 cardinal successful CarbonSmart merchandise revenue.

→ AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be

Biorefining gross accrued from $2.9 cardinal successful the prior-year period, driven by higher engineering and different services revenue. Joint improvement and declaration probe gross declined from $2.3 cardinal arsenic projects with existing customers were completed. CarbonSmart merchandise gross was fundamentally unchanged twelvemonth implicit year.

Cost of gross roseate to $7.2 cardinal from $6.2 million, chiefly owed to higher engineering and services costs and a humble summation successful costs tied to CarbonSmart merchandise sales. Gross nett was $1.8 million, producing an astir 20% gross margin, compared with gross nett of $2.9 cardinal successful the prior-year quarter.

→ Joby's Defense Pivot Accelerates With $500M Resonant Sciences Deal

For the archetypal six months of 2026, full gross accrued 13% to $21 cardinal from $18.6 million. First-half gross nett was $5.6 million, oregon a 26% gross margin, compared with $4.8 cardinal successful the year-earlier period.

Research and improvement disbursal fell to $2 cardinal successful the 2nd 4th from $14.9 cardinal a twelvemonth earlier, portion selling, wide and administrative disbursal declined to $8.8 cardinal from $19.1 million. Chief Financial Officer Sushmita Koyanagi attributed the reductions to workforce cuts, little contractor and outer R&D spending, little ineligible and nonrecreational fees, and reduced facilities-related costs.